Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated:  12/31/1969
University of California at Davis Health System
mi
from
Sacramento, CA
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated: 12/31/1969
University of California at Davis Health System
mi
from
Sacramento, CA
Click here to add this to my saved trials
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated:  12/31/1969
Somero Research Corporation
mi
from
Palm Desert, CA
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated: 12/31/1969
Somero Research Corporation
mi
from
Palm Desert, CA
Click here to add this to my saved trials
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated:  12/31/1969
Idaho Falls Infectious Diseases PLLC
mi
from
Idaho Falls, ID
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated: 12/31/1969
Idaho Falls Infectious Diseases PLLC
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated:  12/31/1969
Springfield Clinic, LLP
mi
from
Springfield, IL
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated: 12/31/1969
Springfield Clinic, LLP
mi
from
Springfield, IL
Click here to add this to my saved trials
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated:  12/31/1969
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated: 12/31/1969
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Click here to add this to my saved trials
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated:  12/31/1969
University of Maryland School of Medicine
mi
from
Baltimore, MD
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated: 12/31/1969
University of Maryland School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated:  12/31/1969
UMASS Memorial Medical Center
mi
from
Worcester, MA
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated: 12/31/1969
UMASS Memorial Medical Center
mi
from
Worcester, MA
Click here to add this to my saved trials
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated:  12/31/1969
Hospital Britanico de Buenos Aires
mi
from
Capital Federal,
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Status: Enrolling
Updated: 12/31/1969
Hospital Britanico de Buenos Aires
mi
from
Capital Federal,
Click here to add this to my saved trials
Piperacillin/Tazobactam for Bacteremia With Organisms Producing Chromosomally-Encoded AmpC Beta-Lactamase
Piperacillin/Tazobactam for Bacteremia With Organisms Producing Chromosomally-Encoded AmpC Beta-Lactamase
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Piperacillin/Tazobactam for Bacteremia With Organisms Producing Chromosomally-Encoded AmpC Beta-Lactamase
Piperacillin/Tazobactam for Bacteremia With Organisms Producing Chromosomally-Encoded AmpC Beta-Lactamase
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin
Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin
Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Eustachian Tube Growth and Development
Eustachian Tube Growth and Development: Anatomy/Function
Status: Enrolling
Updated:  12/31/1969
ENT Research Center, Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Eustachian Tube Growth and Development
Eustachian Tube Growth and Development: Anatomy/Function
Status: Enrolling
Updated: 12/31/1969
ENT Research Center, Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Quinolone Resistance in Bloodstream Isolates of Escherichia Coli
Quinolone Resistance in Bloodstream Isolates of Escherichia Coli
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Quinolone Resistance in Bloodstream Isolates of Escherichia Coli
Quinolone Resistance in Bloodstream Isolates of Escherichia Coli
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram
Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram
Status: Enrolling
Updated:  12/31/1969
OV-UCLA Medical Center
mi
from
Sylmar, CA
Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram
Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram
Status: Enrolling
Updated: 12/31/1969
OV-UCLA Medical Center
mi
from
Sylmar, CA
Click here to add this to my saved trials
Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia
Fatigue and Symptom Burden in Febrile Neutropenia
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia
Fatigue and Symptom Burden in Febrile Neutropenia
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated:  12/31/1969
University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated: 12/31/1969
University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated:  12/31/1969
Veterans Administration Long Beach Medical Center
mi
from
Long Beach, CA
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated: 12/31/1969
Veterans Administration Long Beach Medical Center
mi
from
Long Beach, CA
Click here to add this to my saved trials
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated:  12/31/1969
Veterans Administration Los Angeles Healthcare System
mi
from
Los Angeles, CA
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated: 12/31/1969
Veterans Administration Los Angeles Healthcare System
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated:  12/31/1969
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated: 12/31/1969
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated:  12/31/1969
University of California, San Diego
mi
from
San Diego, CA
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated: 12/31/1969
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Duke Autoimmunity in Pregnancy Registry
Duke Autoimmunity in Pregnancy Registry
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Duke Autoimmunity in Pregnancy Registry
Duke Autoimmunity in Pregnancy Registry
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Risk Factors for Quinolone Resistance Among ESBL Producing Klebsiella Species
Risk Factors for Quinolone Resistance Among Extended-Spectrum Beta-Lactamase-Producing Klebsiella Species
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Risk Factors for Quinolone Resistance Among ESBL Producing Klebsiella Species
Risk Factors for Quinolone Resistance Among Extended-Spectrum Beta-Lactamase-Producing Klebsiella Species
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Risk Factors for Linezolid Resistance in Staphylococcus Aureus
Risk Factors for Linezolid Resistance in Staphylococcus Aureus
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Risk Factors for Linezolid Resistance in Staphylococcus Aureus
Risk Factors for Linezolid Resistance in Staphylococcus Aureus
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Multinational Study of Acinetobacter Bloodstream Infection: Clinical Outcomes and Global Epidemiology-PITT Protocol
Multinational Study of Acinetobacter Bloodstream Infection: Clinical Outcomes and Global Epidemiology-PITT Protocol
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Multinational Study of Acinetobacter Bloodstream Infection: Clinical Outcomes and Global Epidemiology-PITT Protocol
Multinational Study of Acinetobacter Bloodstream Infection: Clinical Outcomes and Global Epidemiology-PITT Protocol
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV
A Randomized, Open-label, Crossover Trial of the Effect of Dosing of Daily HSV-2 Suppressive Therapy on HSV Reactivation and Plasma HIV-1 Levels Among HIV-1/ HSV-2 Co-infected Persons
Status: Enrolling
Updated:  12/31/1969
University of Washington Virology Research Clinic
mi
from
Seattle, WA
Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV
A Randomized, Open-label, Crossover Trial of the Effect of Dosing of Daily HSV-2 Suppressive Therapy on HSV Reactivation and Plasma HIV-1 Levels Among HIV-1/ HSV-2 Co-infected Persons
Status: Enrolling
Updated: 12/31/1969
University of Washington Virology Research Clinic
mi
from
Seattle, WA
Click here to add this to my saved trials
Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia Coli
Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia Coli
Status: Enrolling
Updated:  12/31/1969
UPMC
mi
from
Pittsburgh, PA
Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia Coli
Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia Coli
Status: Enrolling
Updated: 12/31/1969
UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms
Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms
Status: Enrolling
Updated:  12/31/1969
UPMC
mi
from
Pittsburgh, PA
Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms
Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms
Status: Enrolling
Updated: 12/31/1969
UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Yale University
mi
from
New Haven, CT
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine (VEE C-84) as a Booster to VEE TC-83
A Phase 2 Open-Label, Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI-GSD 205 When Used as a Booster After TC-83 Primary Immunization in Healthy Adults At-Risk for Exposure to Virulent Venezuelan Equine Encephalomyelitis Virus
Status: Enrolling
Updated:  12/31/1969
U.S. Army Medical Research Institute of Infectious Diseases
mi
from
Fort Deterick, MD
Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine (VEE C-84) as a Booster to VEE TC-83
A Phase 2 Open-Label, Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI-GSD 205 When Used as a Booster After TC-83 Primary Immunization in Healthy Adults At-Risk for Exposure to Virulent Venezuelan Equine Encephalomyelitis Virus
Status: Enrolling
Updated: 12/31/1969
U.S. Army Medical Research Institute of Infectious Diseases
mi
from
Fort Deterick, MD
Click here to add this to my saved trials
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
University of California at Los Angeles
mi
from
Los Angeles, CA
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
Yale University
mi
from
New Haven, CT
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
Indiana University
mi
from
Indianapolis, IN
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
University of Iowa
mi
from
Iowa City, IA
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
Wayne State University
mi
from
Detroit, MI
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
Children's Mercy Hospital
mi
from
Kansas City, MO
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
University of New Mexico
mi
from
Albuquerque, NM
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
University of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
University of Rochester
mi
from
Rochester, NY
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
RTI International
mi
from
Durham, NC
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
RTI International
mi
from
Durham, NC
Click here to add this to my saved trials
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
Duke University
mi
from
Durham, NC
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
The Research Institute at Nationwide Children's Hospital
mi
from
Columbus, OH
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
The Research Institute at Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
Univeristy of Pennsylvania
mi
from
Philadelphia, PA
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
Univeristy of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
Brown University, Women & Infants Hospital of Rhode Island
mi
from
Providence, RI
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
Brown University, Women & Infants Hospital of Rhode Island
mi
from
Providence, RI
Click here to add this to my saved trials
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
UT Southwestern Medical Center
mi
from
Dallas, TX
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
UT Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials